Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-...

Full description

Bibliographic Details

Main Authors:	Konstantin Schlick, Florian Hohla, Frank Hamacher, Hubert Hackl, Clemens Hufnagl, Steiner Markus, Teresa Magnes, Simon Peter Gampenrieder, Thomas Melchardt, Stefan Stättner, Cornelia Hauser-Kronberger, Richard Greil, Gabriel Rinnerthaler
Format:	Artigo
Language:	Inglês
Published:	Taylor & Francis Group 2021-02-01
Series:	Future Science OA
Subjects:	FOLFIRINOX gemcitabine miRNA pancreatic cancer
Online Access:	https://www.future-science.com/doi/10.2144/fsoa-2020-0128
Tags:	Add Tag No Tags, Be the first to tag this record!